MedTrace Logo

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone

NCT01099748 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2010-08-30

No results posted yet for this study

Summary

The objective of this study is to estimate the effect of lersivirine on the pharmacokinetics of R-methadone and S-methadone and to investigate the safety and tolerability of lersivirine when co-administered with methadone. Symptoms of methadone withdrawal will also be assessed.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Methadone

Methadone 50 - 150 mg QD (Day 1)

DRUG

Lersivirine + Methadone

Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01099748 on ClinicalTrials.gov